niacinamide and lb-100

niacinamide has been researched along with lb-100 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bai, XL; Chen, ZL; Fu, QH; Li, GG; Liang, TB; Lou, Y; Sun, X; Zhang, JY; Zhang, Q	1

Other Studies

1 other study(ies) available for niacinamide and lb-100

Article	Year
LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Smad3 Protein; Sorafenib; Xenograft Model Antitumor Assays	2016

Article

Year

LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Smad3 Protein; Sorafenib; Xenograft Model Antitumor Assays

2016